Hongwei Wang

Dr. Hongwei Wang


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2025 in Translational Oncology
Verified
Journal Article
Open access
JXJing Xu
Jing Xu
FRFanggang Ren
Fanggang Ren
JWJinjuan Wang
Jinjuan Wang
JLJianbing Liu
Jianbing Liu
XCXiaohua Cui
Xiaohua Cui
HWHongwei Wang
Hongwei Wang
Acute myeloid leukemia (AML) is the most prevalent kind of acute leukemia in adults. Despite the availability of new targeted therapies, AML remains connected with a poor prognosis and decreased rate of survival. Tubeimoside I (TBMS1), a critical compound extracted from Bolbostemma paniculatum, has demonstrated potential anticancer effects in lung and colorectal cancers. Nevertheless, the TBMS1 anticancer pathway against AML is still elusive. This study aimed to explore the potential role of TBMS1 in anti-AML and its molecular mechanism. In vitro, TBMS1 treatment suppressed AML cells proliferation, induced apoptosis, and mitochondrial damage, and elevated ROS levels. Network pharmacological analysis suggested, and subsequent studies confirmed, that TBMS1 induced mitophagy in AML cells by modulating the PINK1/Parkin/Mfnh2 signaling pathway, an effect that was effectively reversed following PINK1 knockdown. In vivo, TBMS1 treatment suppressed the proliferation of AML cells after 21 days, improved the survival rates of nude mice, and showed no evident organ toxicity. These evidences suggest that TBMS1 may have significant therapeutic potential in treating AML.

22 May 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JCJiangxia Cui
Jiangxia Cui
SBSicheng Bian
Sicheng Bian
ZHZhuanghui Hao
Zhuanghui Hao
XZXialin Zhang
Xialin Zhang
CZChen Zhang
Chen Zhang
HWHongwei Wang
Hongwei Wang
This study investigates the mechanisms underlying myeloma bone disease (MBD) in multiple myeloma (MM), focusing on myeloma cell-derived exosomes and liquid biopsy biomarkers to identify therapeutic targets for reducing osteoclast activity and enhancing bone homeostasis. Co-culture of OPM2, RPMI 8226, and NCI-H929 myeloma cell lines with THP-1 cells was employed to assess miR4261 and Perox iredoxin Activated in M-CSF-stimulated monocytes (PAMM) expression via RT-qPCR. Dual-luciferase assays confirmed miR4261 binding to the 3’-untranslated region (3’-UTR) of PAMM. THP-1 cells transfected with miR4261 mimics or shPAMM vectors, and treated with M-CSF and RANKL, exhibited enhanced osteoclast differentiation, as evaluated by TRAP staining and micro-CT analysis of bone mineral content (BMC) and tissue mineral content (TMC). Elevated miR4261 expression in MBD patients negatively correlated with PAMM expression, promoting bone resorption. Gene ontology-based gene set enrichment analysis (GO-GSEA) revealed downregulation of genes negatively regulating osteoclast differentiation in the shPAMM group. The miR4261/PAMM axis drives MBD by enhancing osteoclast activity, suggesting dual targeting of miR4261 and PAMM as a potential therapeutic strategy to mitigate bone destruction in MM.